| dc.rights.license | open | en_US |
| dc.contributor.author | HANEY, Margaret | |
| hal.structure.identifier | Neurocentre Magendie : Physiopathologie de la Plasticité Neuronale [U1215 Inserm - UB] | |
| dc.contributor.author | VALLÉE, Monique | |
| dc.contributor.author | FABRE, Sandy | |
| dc.contributor.author | COLLINS REED, Stephanie | |
| dc.contributor.author | ZANESE, Marion | |
| dc.contributor.author | CAMPISTRON, Ghislaine | |
| dc.contributor.author | AROUT, Caroline A | |
| dc.contributor.author | FOLTIN, Richard W | |
| dc.contributor.author | COOPER, Ziva D | |
| dc.contributor.author | KEARNEY-RAMOS, Tonisha | |
| dc.contributor.author | METNA, Mathilde | |
| dc.contributor.author | JUSTINOVA, Zuzana | |
| dc.contributor.author | SCHINDLER, Charles | |
| dc.contributor.author | HEBERT-CHATELAIN, Etienne | |
| hal.structure.identifier | Neurocentre Magendie : Physiopathologie de la Plasticité Neuronale [U1215 Inserm - UB] | |
| dc.contributor.author | BELLOCCHIO, Luigi | |
| hal.structure.identifier | Neurocentre Magendie : Physiopathologie de la Plasticité Neuronale [U1215 Inserm - UB] | |
| dc.contributor.author | CATHALA, Adeline | |
| dc.contributor.author | BARI, Andrea | |
| dc.contributor.author | SERRAT, Roman | |
| dc.contributor.author | FINLAY, David B | |
| hal.structure.identifier | Neurocentre Magendie : Physiopathologie de la Plasticité Neuronale [U1215 Inserm - UB] | |
| dc.contributor.author | CARACI, Filippo | |
| hal.structure.identifier | Neurocentre Magendie : Physiopathologie de la Plasticité Neuronale [U1215 Inserm - UB] | |
| dc.contributor.author | REDON, Bastien | |
| dc.contributor.author | MARTÍN-GARCÍA, Elena | |
| hal.structure.identifier | Neurocentre Magendie : Physiopathologie de la Plasticité Neuronale [U1215 Inserm - UB] | |
| dc.contributor.author | BUSQUETS-GARCIA, Arnau | |
| hal.structure.identifier | Neurocentre Magendie : Physiopathologie de la Plasticité Neuronale [U1215 Inserm - UB] | |
| dc.contributor.author | MATIAS, Isabelle | |
| dc.contributor.author | LEVIN, Frances R | |
| dc.contributor.author | FELPIN, François-Xavier | |
| dc.contributor.author | SIMON, Nicolas | |
| hal.structure.identifier | Neurocentre Magendie : Physiopathologie de la Plasticité Neuronale [U1215 Inserm - UB] | |
| dc.contributor.author | COTA, Daniela | |
| hal.structure.identifier | Neurocentre Magendie : Physiopathologie de la Plasticité Neuronale [U1215 Inserm - UB] | |
| dc.contributor.author | SPAMPINATO, Umberto | |
| dc.contributor.author | MALDONADO, Rafael | |
| dc.contributor.author | SHAHAM, Yavin | |
| dc.contributor.author | GLASS, Michelle | |
| dc.contributor.author | THOMSEN, Lars Lykke | |
| dc.contributor.author | MENGEL, Helle | |
| hal.structure.identifier | Neurocentre Magendie : Physiopathologie de la Plasticité Neuronale [U1215 Inserm - UB] | |
| dc.contributor.author | MARSICANO, Giovanni | |
| dc.contributor.author | MONLEZUN, Stéphanie | |
| hal.structure.identifier | Neurocentre Magendie : Physiopathologie de la Plasticité Neuronale [U1215 Inserm - UB] | |
| dc.contributor.author | REVEST, Jean-Michel | |
| dc.contributor.author | PIAZZA, Pier Vincenzo | |
| dc.date.accessioned | 2024-01-08T14:40:49Z | |
| dc.date.available | 2024-01-08T14:40:49Z | |
| dc.date.issued | 2023-06-01 | |
| dc.identifier.issn | 1546-170X | en_US |
| dc.identifier.other | https://doi.org/10.1038/ s41591-023-02381-w. | en_US |
| dc.identifier.uri | https://oskar-bordeaux.fr/handle/20.500.12278/186944 | |
| dc.description.abstractEn | Cannabis use disorder (CUD) is widespread, and there is no pharmacotherapy to facilitate its treatment. AEF0117, the first of a new pharmacological class, is a signaling-specific inhibitor of the cannabinoid receptor 1 (CB-SSi). AEF0117 selectively inhibits a subset of intracellular effects resulting from Δ-tetrahydrocannabinol (THC) binding without modifying behavior per se. In mice and non-human primates, AEF0117 decreased cannabinoid self-administration and THC-related behavioral impairment without producing significant adverse effects. In single-ascending-dose (0.2 mg, 0.6 mg, 2 mg and 6 mg; n = 40) and multiple-ascending-dose (0.6 mg, 2 mg and 6 mg; n = 24) phase 1 trials, healthy volunteers were randomized to ascending-dose cohorts (n = 8 per cohort; 6:2 AEF0117 to placebo randomization). In both studies, AEF0117 was safe and well tolerated (primary outcome measurements). In a double-blind, placebo-controlled, crossover phase 2a trial, volunteers with CUD were randomized to two ascending-dose cohorts (0.06 mg, n = 14; 1 mg, n = 15). AEF0117 significantly reduced cannabis' positive subjective effects (primary outcome measurement, assessed by visual analog scales) by 19% (0.06 mg) and 38% (1 mg) compared to placebo (P < 0.04). AEF0117 (1 mg) also reduced cannabis self-administration (P < 0.05). In volunteers with CUD, AEF0117 was well tolerated and did not precipitate cannabis withdrawal. These data suggest that AEF0117 is a safe and potentially efficacious treatment for CUD.ClinicalTrials.gov identifiers: NCT03325595 , NCT03443895 and NCT03717272 . | |
| dc.description.sponsorship | Bordeaux Region Aquitaine Initiative for Neuroscience | en_US |
| dc.language.iso | EN | en_US |
| dc.rights | Attribution 3.0 United States | * |
| dc.rights.uri | http://creativecommons.org/licenses/by/3.0/us/ | * |
| dc.subject.en | Animals | |
| dc.subject.en | Mice | |
| dc.subject.en | Cannabis | |
| dc.subject.en | Double-Blind Method | |
| dc.subject.en | Dronabinol | |
| dc.subject.en | Hallucinogens | |
| dc.subject.en | Marijuana Abuse | |
| dc.subject.en | Randomized Controlled Trials as Topic | |
| dc.subject.en | Substance Withdrawal Syndrome | |
| dc.title.en | Signaling-specific inhibition of the CB1 receptor for cannabis use disorder: phase 1 and phase 2a randomized trials | |
| dc.title.alternative | Nat Med | en_US |
| dc.type | Article de revue | en_US |
| dc.identifier.doi | 10.1038/s41591-023-02381-w. | en_US |
| dc.subject.hal | Sciences du Vivant [q-bio]/Neurosciences [q-bio.NC] | en_US |
| dc.identifier.pubmed | 37291212 | en_US |
| bordeaux.journal | Nature Medicine | en_US |
| bordeaux.page | 1487-1499 | en_US |
| bordeaux.volume | 29 | en_US |
| bordeaux.hal.laboratories | Neurocentre Magendie - U1215 | en_US |
| bordeaux.issue | 6 | en_US |
| bordeaux.institution | Université de Bordeaux | en_US |
| bordeaux.institution | CNRS | en_US |
| bordeaux.institution | INSERM | en_US |
| bordeaux.team | Endocannabinoïdes et Neuroadaptation | en_US |
| bordeaux.team | Physiopathologie de l'équilibre énergétique et obésité | en_US |
| bordeaux.team | Physiopathologie et approches thérapeutiques des maladies liées au stress | en_US |
| bordeaux.team | Chimie analytique | en_US |
| bordeaux.peerReviewed | oui | en_US |
| bordeaux.inpress | non | en_US |
| bordeaux.identifier.funderID | Mission Interministérielle de Lutte Contre les Drogues et les Conduites Addictives | en_US |
| bordeaux.identifier.funderID | Conseil Régional Aquitaine | en_US |
| bordeaux.identifier.funderID | Ministerio de Sanidad, Servicios Sociales e Igualdad | en_US |
| bordeaux.identifier.funderID | Plan Nacional sobre Drogas | en_US |
| bordeaux.import.source | pubmed | |
| hal.popular | non | en_US |
| hal.audience | Internationale | en_US |
| hal.export | false | |
| workflow.import.source | pubmed | |
| dc.rights.cc | CC BY | en_US |
| bordeaux.COinS | ctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=Nature%20Medicine&rft.date=2023-06-01&rft.volume=29&rft.issue=6&rft.spage=1487-1499&rft.epage=1487-1499&rft.eissn=1546-170X&rft.issn=1546-170X&rft.au=HANEY,%20Margaret&VALL%C3%89E,%20Monique&FABRE,%20Sandy&COLLINS%20REED,%20Stephanie&ZANESE,%20Marion&rft.genre=article | |
